By Katherine Hamilton
Grove Collaborative received a letter from activist investor HumanCo Investments calling for a review of strategic alternatives, including a sale of the company.
HumanCo, which owns more than 5% of Grove, said Tuesday that the health and wellness company is undervalued in the public market due to a lack of investor relevance as a result of its small market capitalization.
The company has not pursued a strategy that balances growth and profitability due to its operational and public cost burden, which can't be reduced as a standalone public company, HumanCo said.
Grove might be valued at a 90% to 140% premium to its current share price, HumanCo said. Grove shares soared 52% to $1.74 post market, and ended the regular trading session down 1.7% at $1.50. Through the close shares are down 16% this year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
July 08, 2025 16:46 ET (20:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。